欧洲091011上市药品.docx
- 文档编号:30181507
- 上传时间:2023-08-05
- 格式:DOCX
- 页数:18
- 大小:20.53KB
欧洲091011上市药品.docx
《欧洲091011上市药品.docx》由会员分享,可在线阅读,更多相关《欧洲091011上市药品.docx(18页珍藏版)》请在冰豆网上搜索。
欧洲091011上市药品
NameoftheMedicinalProduct
ChondroCelect
MarketingAuthorisationHolder
TiGenixNV
Romeinsestraat12bus2
BE-3001Leuven
Belgium
ActiveSubstance
characterisedviableautologouscartilagecellsexpandedexvivoexpressingspecificmarkerproteins
InternationalNonproprietaryNameorCommonName
characterisedviableautologouscartilagecellsexpandedexvivoexpressingspecificmarkerproteins
Pharmaco-therapeuticGroup
--
ATCCode
--
TherapeuticIndication
Repairofsinglesymptomaticcartilagedefectsofthefemoralcondyleoftheknee(InternationalCartilageRepairSociety[ICRS]gradeIIIorIV)inadults.Concomitantasymptomaticcartilagelesions(ICRSgradeIorII)mightbepresent.DemonstrationofefficacyisbasedonarandomisedcontrolledtrialevaluatingtheefficacyofChondrocelectinpatientswithlesionsbetween1-5cm².
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
05October2009
Orphanmedicinalproductdesignationdate
Notapplicable
ProductOverview
NameoftheMedicinalProduct
Cimzia
MarketingAuthorisationHolder
UCBPharmaSA
AlléedelaRecherche60
B-1070Bruxelles
Belgium
ActiveSubstance
certolizumabpegol
InternationalNonproprietaryNameorCommonName
certolizumabpegol
Pharmaco-therapeuticGroup
Tumornecrosisfactoralpha(TNF-α)inhibitors
ATCCode
L04AB05
TherapeuticIndication
Cimzia,incombinationwithmethotrexate(MTX),isindicatedforthetreatmentofmoderatetosevere,activerheumatoidarthritis(RA)inadultpatientswhentheresponsetodisease-modifyingantirheumaticdrugs(DMARDs)includingmethotrexate,hasbeeninadequate.
Cimziacanbegivenasmonotherapyincaseofintolerancetomethotrexateorwhencontinuedtreatmentwithmethotrexateisinappropriate.
CimziahasbeenshowntoreducetherateofprogressionofjointdamageasmeasuredbyX-rayandtoimprovephysicalfunction,whengivenincombinationwithmethotrexate.
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
1October2009
Orphanmedicinalproductdesignationdate
Notapplicable
ProductOverview
NameoftheMedicinalProduct
ClopidogrelMYLANPharma
MarketingAuthorisationHolder
MylanS.A.S.
117alléedesParcs
F-69800SaintPriest
France
ActiveSubstance
clopidogrelbesilate
InternationalNonproprietaryNameorCommonName
clopidogrel
Pharmaco-therapeuticGroup
Plateletaggregationinhibitorsexcl.heparin
ATCCode
B01AC04
TherapeuticIndication
Clopidogrelisindicatedinadultsforthepreventionofatherothromboticeventsin:
-Patientssufferingfrommyocardialinfarction(fromafewdaysuntillessthan35days),ischaemicstroke(from7daysuntillessthan6months)orestablishedperipheralarterialdisease.
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
16October2009
Orphanmedicinalproductdesignationdate
Notapplicable
ProductOverview
NameoftheMedicinalProduct
CopaliaHCT
MarketingAuthorisationHolder
NovartisEuropharmLimited
WimblehurstRoad
Horsham
WestSussexRH125AB
UnitedKingdom
ActiveSubstance
amlodipinebesylate/valsartan/hydrochlorothiazide
InternationalNonproprietaryNameorCommonName
amlodipinebesylate/valsartan/hydrochlorothiazide
Pharmaco-therapeuticGroup
AngiotensinIIantagonists,plain(valsartan),combinationswithdihydropyridinederivatives(amlodipine)andthiazidediuretics(hydrochlorothiazide)
ATCCode
C09DX01
TherapeuticIndication
Treatmentofessentialhypertensionassubstitutiontherapyinadultpatientswhosebloodpressureisadequatelycontrolledonthecombinationofamlodipine,valsartanandhydrochlorothiazide(HCT),takeneitherasthreesingle-componentformulationsorasadual-componentandasingle-componentformulation.
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
4November2009
Orphanmedicinalproductdesignationdate
Notapplicable
ProductOverview
NameoftheMedicinalProduct
DafiroHCT
MarketingAuthorisationHolder
NovartisEuropharmLimited
WimblehurstRoad
Horsham
WestSussexRH125AB
UnitedKingdom
ActiveSubstance
amlodipinebesylate/valsartan/hydrochlorothiazide
InternationalNonproprietaryNameorCommonName
amlodipinebesylate/valsartan/hydrochlorothiazide
Pharmaco-therapeuticGroup
AngiotensinIIantagonists,plain(valsartan),combinationswithdihydropyridinederivatives(amlodipine)andthiazidediuretics(hydrochlorothiazide)
ATCCode
C09DX01
TherapeuticIndication
Treatmentofessentialhypertensionassubstitutiontherapyinadultpatientswhosebloodpressureisadequatelycontrolledonthecombinationofamlodipine,valsartanandhydrochlorothiazide(HCT),takeneitherasthreesingle-componentformulationsorasadual-componentandasingle-componentformulation.
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
4November2009
Orphanmedicinalproductdesignationdate
Notapplicable
NameoftheMedicinalProduct
ExforgeHCT
MarketingAuthorisationHolder
NovartisEuropharmLimited
WimblehurstRoad
Horsham
WestSussexRH125AB
UnitedKingdom
ActiveSubstance
amlodipinebesylate/valsartan/hydrochlorothiazide
InternationalNonproprietaryNameorCommonName
amlodipinebesylate/valsartan/hydrochlorothiazide
Pharmaco-therapeuticGroup
AngiotensinIIantagonists,plain(valsartan),combinationswithdihydropyridinederivatives(amlodipine)andthiazidediuretics(hydrochlorothiazide)
ATCCode
C09DX01
TherapeuticIndication
Treatmentofessentialhypertensionassubstitutiontherapyinadultpatientswhosebloodpressureisadequatelycontrolledonthecombinationofamlodipine,valsartanandhydrochlorothiazide(HCT),takeneitherasthreesingle-componentformulationsorasadual-componentandasingle-componentformulation.
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
16October2009
Orphanmedicinalproductdesignationdate
Notapplicable
ProductOverview
NameoftheMedicinalProduct
Ilaris
MarketingAuthorisationHolder
NovartisEuropharmLtd.
WimblehurstRoad
Horsham,WSussexRH125AB
UnitedKingdom
ActiveSubstance
canakinumab
InternationalNonproprietaryNameorCommonName
canakinumab
Pharmaco-therapeuticGroup
Interleukininhibitors
ATCCode
L04AC08
TherapeuticIndication
IlarisisindicatedforthetreatmentofCryopyrin-AssociatedPeriodicSyndromes(CAPS)inadults,adolescentsandchildrenaged4yearsandolderwithbodyweightabove15kg,including:
-Muckle-WellsSyndrome(MWS),
-Neonatal-OnsetMultisystemInflammatoryDisease(NOMID)/ChronicInfantileNeurological,Cutaneous,ArticularSyndrome(CINCA),
-SevereformsofFamilialColdAutoinflammatorySyndrome(FCAS)/FamilialColdUrticaria(FCU)presentingwithsignsandsymptomsbeyondcold-inducedurticarialskinrash.
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
23October2009
Orphanmedicinalproductdesignationdate
20March2007
ProductOverview
NameoftheMedicinalProduct
ImpridaHCT
MarketingAuthorisationHolder
NovartisEuropharmLimited
WimblehurstRoad
Horsham
WestSussexRH125AB
UnitedKingdom
ActiveSubstance
amlodipinebesylate/valsartan/hydrochlorothiazide
InternationalNonproprietaryNameorCommonName
amlodipinebesylate/valsartan/hydrochlorothiazide
Pharmaco-therapeuticGroup
AngiotensinIIantagonists,plain(valsartan),combinationswithdihydropyridinederivatives(amlodipine)andthiazidediuretics(hydrochlorothiazide)
ATCCode
C09DX01
TherapeuticIndication
Treatmentofessentialhypertensionassubstitutiontherapyinadultpatientswhosebloodpressureisadequatelycontrolledonthecombinationofamlodipine,valsartanandhydrochlorothiazide(HCT),takeneitherasthreesingle-componentformulationsorasadual-componentandasingle-componentformulation
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
15October2009
Orphanmedicinalproductdesignationdate
Notapplicable
ProductOverview
NameoftheMedicinalProduct
IrbesartanTeva
MarketingAuthorisationHolder
TevaPharmaB.V.
Computerweg10
NL-3542DRUtrecht
TheNetherlands
ActiveSubstance
irbesartan
InternationalNonproprietaryNameorCommonName
irbesartan
Pharmaco-therapeuticGroup
AngiotensinIIantagonists,plain
ATCCode
C09CA04
TherapeuticIndication
Treatmentofessentialhypertension.
Treatmentofrenaldiseaseinpatientswithhypertensionandtype2diabetesmellitusaspartofanantihypertensivemedicinalproductregimen(seesection5.1).
DateofissueofMarketingAuthorisationvalidthroughouttheEuropeanUnion
30October2009
Orphanmedicinalproductdesignationdate
Notapplicable
ProductOverview
NameoftheMedicinalProduct
LamivudineTeva
MarketingAuthorisationHolder
TevaPharmaB.V.
Computerweg10
NL-3542DRUtrecht
TheNetherlands
ActiveSubstance
lamivudine
InternationalNonproprietaryNameorCommonName
lamivudine
Pharmaco-therapeuticGroup
Nucleosideandnucleotidereversetranscriptaseinhibitors
ATCCode
J05AF05
TherapeuticIndication
LamivudineTevaisindicatedforthetreatmentofchronichepatitisBinadultswith:
-compensatedliverdiseasewithevidenceofactiveviralreplication,persistentlyelevatedserumalanineaminotransferase(ALT)levelsandhistologicalevidenceofactiveliverinflammationand/orfibrosis.
-decompensatedliverdisease.
DateofissueofMarketingAuthorisationvalidthroughouttheEurop
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 欧洲 091011 上市 药品